◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Emcure Pharmaceuticals Limited (EMCURE) Net Income 2022–TTM

Name: Emcure Pharmaceuticals Limited (EMCURE) net income history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-02

Emcure Pharmaceuticals Limited annual net income for fiscal TTM was ₹10.1 billion, an increase of 9.4% from ₹9.2 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

EMCURE Annual Net Income

Net Income (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Net Income	₹10.1B	₹9.2B	₹6.8B	₹5.0B	₹5.3B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EMCURE Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Net Income	₹2.9B	₹2.4B	₹2.3B	₹2.4B	₹2.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

ABBOTINDIA Net Income — Abbott India Limited
GLAND Net Income — Gland Pharma Limited
IPCALAB Net Income — Ipca Laboratories Limited
AJANTPHARM Net Income — Ajanta Pharma Limited
1276 Net Income — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
WOCKPHARMA Net Income — Wockhardt Limited

More EMCURE metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All EMCURE financial statements → Interactive EMCURE charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.